The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Claims The invention claimed is: 1. A compound of formula I: ##STR00928## or a pharmaceutically acceptable salt or derivative thereof, wherein: R.sup.1 and R.sup.2, taken together with the nitrogen atom, form a substituted ring: ##STR00929## wherein, in ring (C): G.sub.3 is ##STR00930## each of m.sub.3 and n.sub.3 is independently 0-3, provided that m.sub.3+n.sub.3 is 2-6; p.sub.3 is 0-2; z.sub.3 is 0-4; each R.sup.XX is hydrogen, C.sub.1-6 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein R.sup.XX is optionally substituted with w.sub.3 independent occurrences of --R.sup.13, wherein w.sub.3 is 0-3; provided that both R.sup.XX are not simultaneously hydrogen; R.sup.YY is hydrogen, --COR', --CO.sub.2R', --CON(R').sub.2, --SOR', --SO.sub.2R', --SO.sub.2N(R').sub.2, --COCOR', --COCH.sub.2COR', --P(O)(OR').sub.2, --P(O).sub.2OR', or --PO(R'), x and y, each, is independently 0-4; W is OR.sup.XY; R.sup.XY is hydrogen or a group selected from: ##STR00931## wherein: each of w.sub.A, w.sub.B, w.sub.c, and w.sub.D is independently 0 or 1; each M is independently selected from hydrogen, Li, Na, K, Mg, Ca, Ba, --N(R.sup.7).sub.4, C.sub.1-C.sub.12-alkyl, C.sub.2-C.sub.12-alkenyl, or --R.sup.6; wherein 1 to 4 --CH.sub.2 radicals of the alkyl or alkenyl group, other than the --CH.sub.2 that is bound to Z, is optionally replaced by a heteroatom group selected from O, S, S(O), S(O.sub.2), or N(R.sup.7); and wherein any hydrogen in said alkyl or alkenyl is optionally replaced with a substituent selected from oxo, --OR', --R.sup.7, N(R.sup.7).sub.2, N(R.sup.7).sub.3, R.sup.7OH, --CN, --CO.sub.2 R.sup.7, --C(O)--N(R.sup.7).sub.2, S(O).sub.2--N(R.sup.7).sub.2, N(R.sup.7)--C(O)--R.sup.7, C(O)R.sup.7, --S(O).sub.n--R.sup.7, OCF.sub.3, --S(O).sub.n--R.sup.6, N(R.sup.7)--S(O).sub.2(R.sup.7), halo, --CF.sub.3, or --NO.sub.2; n is 0-2; M' is H, C.sub.1-C.sub.12-alkyl, C.sub.2-C.sub.12-alkenyl, or --R.sup.6; wherein 1 to 4 --CH.sub.2 radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S, S(O), S(O.sub.2), or N(R.sup.7); and wherein any hydrogen in said alkyl or alkenyl is optionally replaced with a substituent selected from oxo, --OR.sup.7, --R.sup.7, --N(R.sup.7).sub.2, N(R.sup.7).sub.3, --R.sup.7OH, --CN, --CO.sub.2 R.sup.7, --C(O)--N(R.sup.7).sub.2, --S(O).sub.2--N(R.sup.7).sub.2, --N(R.sup.7)--C(O)--R.sup.7, --C(O)R.sup.7, --S(O).sub.n--R.sup.7, --OCF.sub.3, --S(O).sub.n--R.sup.6, --N(R.sup.7)--S(O).sub.2(R.sup.7), halo, --CF.sub.3, or --NO.sub.2; Z is --CH.sub.2--, --O--, --S--, --N(R.sup.7).sub.2--; or, when M is absent, then Z is hydrogen, .dbd.O, or .dbd.S; Y is P or S, wherein when Y is S, then Z is not S; X is O or S; each R.sup.7 is independently selected from hydrogen, or C.sub.1-C.sub.4 aliphatic, optionally substituted with up to two Q.sub.1; each Q.sub.1 is independently selected from a 3-7 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatom or heteroatom group selected from O, N, NH, S, SO, or SO.sub.2; wherein Q.sub.1 is optionally substituted with up to three substituents selected from oxo, --OH, --O(C.sub.1-C.sub.4 aliphatic), --C.sub.1-C.sub.4 aliphatic, --NH.sub.2, NH(C.sub.1-C.sub.4 aliphatic), --N(C.sub.1-C.sub.4 aliphatic).sub.2, --N(C.sub.1-C.sub.4 aliphatic)-C(O)--C.sub.1-C.sub.4 aliphatic, --(C.sub.1-C.sub.4 aliphatic)-OH, --CN, --CO.sub.2H, --CO.sub.2(C.sub.1-C.sub.4 aliphatic), --C(O)--NH.sub.2, --C(O)--NH(C.sub.1-C.sub.4 aliphatic), --C(O)--N(C.sub.1-C.sub.4 aliphatic).sub.2, halo or --CF.sub.3; R.sup.6 is a 5-6 membered saturated, partially saturated or unsaturated carbocyclic or heterocyclic ring system, or an 8-10 membered saturated, partially saturated or unsaturated bicyclic ring system; wherein any of said heterocyclic ring systems contains one or more heteroatoms selected from O, N, S, S(O).sub.n or N(R.sup.7); and wherein any of said ring systems optionally contains 1 to 4 substituents independently selected from OH, C.sub.1-C.sub.4 alkyl, O--C.sub.1-C.sub.4 alkyl or O--C(O)--C.sub.1-C.sub.4 alkyl; R.sup.9 is C(R.sup.7).sub.2, O or N(R.sup.7); each occurrence of R.sup.13, R.sup.3, R.sup.4, and R.sup.5 is independently Q-R.sup.X; wherein Q is a bond or is a C.sub.1-C.sub.6 alkylidene chain wherein up to two non-adjacent methylene units of Q are optionally and independently replaced by --NR--, --S--, --O--, --CS--, --CO.sub.2--, --OCO--, --CO--, --COCO--, --CONR--, --NRCO--, --NRCO.sub.2--, --SO.sub.2NR--, --NRSO.sub.2--, --CONRNR--, --NRCONR--, --OCONR--, --NRNR--, --NRSO.sub.2NR--, --SO--, --SO.sub.2--, --PO--, --PO.sub.2--, --OP(O)(OR)--, or --POR--; and each occurrence of R.sup.X is independently selected from --R', halogen, .dbd.O, .dbd.NR', --NO.sub.2, --CN, --OR', --SR', --N(R').sub.2, --NR'COR', --NR'CON(R').sub.2, --NR'CO.sub.2R', --COR', --CO.sub.2R', --OCOR', --CON(R').sub.2, --OCON(R').sub.2, --SOR', --SO.sub.2R', --SO.sub.2N(R').sub.2, --NR'SO.sub.2R', --NR'SO.sub.2N(R').sub.2, --COCOR', --COCH.sub.2COR', --OP(O)(OR').sub.2, --P(O)(OR').sub.2, --OP(O).sub.2OR', --P(O).sub.2OR', --PO(R').sub.2, or --OPO(R').sub.2; and each occurrence of R is independently hydrogen or C.sub.1-6 aliphatic group having up to three substituents; and each occurrence of R' is independently hydrogen or C.sub.1-6 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein R' has up to four substituents; or R and R', two occurrences of R, or two occurrences of R', are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 2. The compound according to claim 1, wherein W is OH. 3. The compound according to claim 1, wherein x is 1 and R.sup.3 is present at the 6- or 7-position of the quinazoline ring. 4. The compound according to claim 3, wherein R.sup.3 is selected from --Cl, --CH.sub.3, --CH.sub.2CH.sub.3, --F, --CF.sub.3, --OCF.sub.3, --CONHCH.sub.3, --CONHCH.sub.2CH.sub.3, --CONH(cyclopropyl), --OCH.sub.3, --NH.sub.2, --OCH.sub.2CH.sub.3, or --CN. 5. The compound according to claim 4, wherein x is 1 and R.sup.3 is at the 7-position of the quinazoline ring and is --CH.sub.3. 6. The compound according to claim 1, wherein y is 0. 7. The compound according to claim 1, wherein y is 1, and R.sup.5 is halo. 8. The compound according to claim 7, wherein R.sup.5 is halo at the 6-position. 9. The compound according to claim 1, wherein z.sub.3 is 0. 10. The compound according to claim 1, wherein said compound has formula I-C: ##STR00932## 11. The compound according to claim 10, wherein one R.sup.XX is hydrogen and the other R.sup.XX is not hydrogen. 12. The compound according to claim 10, wherein one R.sup.XX is hydrogen and the other R.sup.XX is C1-C6 alkyl optionally substituted with halo. 13. The compound according to claim 10, wherein both R.sup.XX are simultaneously C1-C6 alkyl. 14. The compound according to claim 12 or 13, wherein said alkyl is selected from methyl, ethyl, isopropyl, n-propyl, n-butyl, sec-butyl, or t-butyl. 15. The compound according to claim 10, wherein p.sub.3 is 0. 16. The compound according to claim 10, wherein m.sub.3 and n.sub.3 each is 2. 17. The compound according to claim 10, wherein R.sup.YY is hydrogen. 18. The compound according to claim 10, wherein said compound has formula I-C-i: ##STR00933## 19. The compound according to claim 18, wherein R.sup.XX is C1-C6 alkyl. 20. The compound according to claim 18, wherein x is 1, and R.sup.3 is C1-C4 alkyl at the 7-position. 21. The compound according to claim 18, wherein x is 1 and R.sup.3 is F, CN, or CF.sub.3 at the 6-position. 22. The compound according to claim 18, wherein R.sup.XX is methyl, n-propyl, isopropyl, n-butyl, sec-butyl, or t-butyl. 23. The compound according to claim 20, wherein R.sup.3 is methyl, n -propyl, isopropyl, n -butyl, sec-butyl, or t-butyl. 24. The compound according to claim 18, wherein R.sup.XY is hydrogen, and y is 0. 25. The compound according to claim 18, wherein R.sup.XY is hydrogen, y is 1 and R.sup.5 is 6-F. 26. The compound according to claim 10, wherein said compound has formula I-C-ii: ##STR00934## 27. The compound according to claim 26, wherein R.sup.3 is methyl at the 7-position of the quinazoline ring. 28. The compound according to claim 26, wherein R.sup.XX is CH.sub.2C(O)OH or CH.sub.2C(O)NH.sub.2. 29. The compound according to claim 1, wherein said compound is selected from: TABLE-US-00005 101 ##STR00935## 102 ##STR00936## 106 ##STR00937## 108 ##STR00938## 109 ##STR00939## 110 ##STR00940## 111 ##STR00941## 112 ##STR00942## 113 ##STR00943## 115 ##STR00944## 118 ##STR00945## 120 ##STR00946## 121 ##STR00947## 122 ##STR00948## 123 ##STR00949## 124 ##STR00950## 125 ##STR00951## 129 ##STR00952## 130 ##STR00953## 131 ##STR00954## 134 ##STR00955## 135 ##STR00956## 136 ##STR00957## 137 ##STR00958## 138 ##STR00959## 139 ##STR00960## 141 ##STR00961## 142 ##STR00962## 143 ##STR00963## 144 ##STR00964## 145 ##STR00965## 146 ##STR00966## 147 ##STR00967## 150 ##STR00968## 151 ##STR00969## 153 ##STR00970## 154 ##STR00971## 155 ##STR00972## 158 ##STR00973## 159 ##STR00974## 164 ##STR00975## 165 ##STR00976## 166 ##STR00977## 167 ##STR00978## 168 ##STR00979## 169 ##STR00980## 170 ##STR00981## 172 ##STR00982## 173 ##STR00983## 174 ##STR00984## 176 ##STR00985## 177 ##STR00986## 178 ##STR00987## 179 ##STR00988## 180 ##STR00989## 181 ##STR00990## 232 ##STR00991## 233 ##STR00992## 234 ##STR00993## 235 ##STR00994## 236 ##STR00995## 237 ##STR00996## 238 ##STR00997## 239 ##STR00998## 240 ##STR00999## 241 ##STR01000## 242 ##STR01001## 243 ##STR01002## 244 ##STR01003## 245 ##STR01004## 246 ##STR01005## 247 ##STR01006## 248 ##STR01007## 249 ##STR01008## 264 ##STR01009## 265 ##STR01010## 266 ##STR01011## 267 ##STR01012## 268 ##STR01013## 269 ##STR01014## 270 ##STR01015## 358 ##STR01016## 359 ##STR01017## 360 ##STR01018## 361 ##STR01019## 30. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier. 31. A compound of formula 101: TABLE-US-00006 101 ##STR01020## 32. A compound of formula 102: TABLE-US-00007 102 ##STR01021## 33. A compound of formula 135: TABLE-US-00008 135 ##STR01022## 34. A compound of formula 168: TABLE-US-00009 168 ##STR01023## 35. A pharmaceutical composition comprising a compound according to claim 29 and a pharmaceutically acceptable carrier. 36. A pharmaceutical composition comprising a compound according to claim 31 and a pharmaceutically acceptable carrier. 37. A pharmaceutical composition comprising a compound according to claim 32 and a pharmaceutically acceptable carrier. 38. A pharmaceutical composition comprising a compound according to claim 33 and a pharmaceutically acceptable carrier. 39. A pharmaceutical composition comprising a compound according to claim 34 and a pharmaceutically acceptable carrier. 